Today Congress passed the FDA Reauthorization Act (FDARA) of 2017. This new legislation reauthorizes the user fee programs necessary for the continued support of the agency’s pre-market evaluation of prescription drugs, medical devices, generic drugs, and biosimilar products. The timely reauthorization of these programs ensures continuity for our medical product review programs and is crucial to supporting our mission of protecting and promoting public health.
This page has been updated recently.
- Influenza Virus Vaccine for the 2017-2018 Season
Updated: 8/3/2017
.png)
No hay comentarios:
Publicar un comentario